QPS Selects Oracle Argus Safety Database
Exhibitor: QPS HOLDINGS, LLC
Date: 2026-05-11
Booth No.: M1213
NEWARK, Del.–(BUSINESS WIRE)–QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials.
The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements.
“Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Derek Grimes, Executive Vice President of QPS. “Oracle Argus provides us with a robust, scalable solution to support the growing needs of our customer’s clinical trial portfolios and the evolving expectations of regulatory authorities worldwide.”
“Oracle Argus provides QPS Holdings, LLC with a trusted, globally recognized drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations, while streamlining end-to-end safety operations and insights at scale,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “With our industry-leading solutions, QPS Holdings, LLC can further transform and elevate its safety case management for customers worldwide.”
The deployment of Oracle Argus will enable QPS to:
- Support clients with best-in-class safety monitoring solutions
- Enhance oversight and traceability across all phases of clinical trials
- Streamline pharmacovigilance workflows and safety case management
- Improve efficiency in regulatory reporting for global submissions
As the demand for innovative therapies continues to rise, CROs play a critical role in managing both development speed and patient safety. By leveraging the Oracle Argus platform, QPS is well-positioned to deliver on its mission to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services.
ABOUT QPS HOLDINGS, LLC
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. For more information, visit https://www.qps.com or email info@qps.com.
ABOUT ORACLE ARGUS
Oracle Argus is an industry-leading, trusted solution for processing, analyzing, and reporting adverse event cases originating in pre-market and post-market drugs, biologics, vaccines, devices, and combination products. Oracle has been a Leader in the IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services 2025 Vendor Assessment (doc # US53669225, July 2025). To learn more about Oracle’s pharmacovigilance portfolio visit: https://www.oracle.com/life-sciences/safety-solutions/argus-safety-case-management/. Trademarks: Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation.
More Exhibitor's Press Release
- With over 30 years of experience in automation equipment RADEN AUTOMATIC LTD. / 2026-05-12
- Common Instruments for Nucleic Acid Concentration Detection MEDCLUB SCIENTIFIC CO., LTD. / 2026-05-12
- Feyond-MF200 Multi-Mode Microplate Reader Launched! MEDCLUB SCIENTIFIC CO., LTD. / 2026-05-12
- Multiplex qPCR vs. Singleplex qPCR: Key Differences, Benefits, and Experimental Considerations MEDCLUB SCIENTIFIC CO., LTD. / 2026-05-12
- QPS Expands Offerings With Robust Pharmacology Disease Models, Including MASH, Ulcerative Colitis, W QPS HOLDINGS, LLC / 2026-05-11
- QPS Celebrates 30th Anniversary QPS HOLDINGS, LLC / 2026-05-11
- Bio-Techne Expands COMET™ Spatial Biology Portfolio with New SPYRE™ Solutions HONG JING CO., LTD. / 2026-05-11
- Bio-Techne Launches Cultrex™ Synthetic Hydrogel to Enhance Reproducibility in 3D Organoid Culture HONG JING CO., LTD. / 2026-05-11
- Aiming for a Guinness World Record! The 3rd International Traditional & Natural Medicine Congress to MEDITHEK ENTERPRISES LTD. / 2026-05-11
- Pharmaceutical Company Donates 3,000 ““AHCHOO” Herbal Sprays to Support Vulnerable Communities Durin MEDITHEK ENTERPRISES LTD. / 2026-05-11
- Rotary International Donates “AHCHOO” Herbal Spray to Tri-Service General Hospital, Supporting Front MEDITHEK ENTERPRISES LTD. / 2026-05-11
- Consumer-Friendly Jelly Formats Redefine Health Supplements with Both Functionality and Enjoyment JOWIN BIOPHARMA, INC. / 2026-05-07
- Highest Cell Viability in Perfusion LEVITRONIX GMBH TAIWAN BRANCH / 2026-05-05
- The Fastest and Safest Depth Filtration LEVITRONIX GMBH TAIWAN BRANCH / 2026-05-05
- Next Generations Therapy Manufacturing LEVITRONIX GMBH TAIWAN BRANCH / 2026-05-05
- Youlin Pharmaceutical Debuts at BIO Asia-Taiwan 2026 — Accelerating New Drug Clinical Development wi SHANGHAI UNIONCLIN CO,. LTD.(UNIONCLIN) / 2026-04-29
- BioLegend Introduces Cell-Vive™ GMP Solutions to Streamline and Scale Cell Therapy Manufacturing BIOLEGEND TAIWAN INC. / 2026-04-28
- Revolutionizing Production Efficiency! Singhania Tableting Unveils One-Stop Smart Tableting Solution ATTRA GIAND INDUSTRIAL CO., LTD. / 2026-04-24
- KMU to Showcase 50+ Cutting-Edge Medical Innovations at BIO Asia–Taiwan 2026 KAOHSIUNG MEDICAL UNIVERSITY / 2026-04-22
- Thermo Fisher Genesys UV Visible Spectrophotometer CHIEFDOM-TEK CO., LTD. / 2026-04-22